- 24 h
- letzte 200 News
| Zeit | Aktuelle Nachrichten | ||
|---|---|---|---|
| Do | Viatris makes foray into non-opioid pain space on $1.65bn Pacira buyout | ||
| Do | Change lifestyle before giving children weight loss medication, WHO says | ||
| Do | FDA approves Pfizer's Tukysa regimen for metastatic breast cancer | ||
| Do | 10x Genomics and Fred Hutch partner on cancer technologies | ||
| Mi | CAR-T specialist Caribou culls pipeline and seeks exit deal | ||
| Mi | KymaThera pulls in $80m to bring breast cancer drug to clinic | ||
| Mi | Rocket receives $150m credit facility to advance cardiovascular portfolio | ||
| Mi | Gilead Sciences signs five-year DevOps agreement with Cognizant | ||
| Di | Shionogi bolsters rare disease portfolio with $2bn IntraBio buyout | ||
| Di | Lilly deepens ties with Gate Bioscience in $870m deal expansion | ||
| Di | Alector shares up after sealing $1.27bn Roche Parkinson's disease license deal | ||
| Di | CSL and Alentis ink $1.5bn partnership to progress antifibrotic drug | ||
| Di | Pacira partners with Molteni for Exparel commercialisation | ||
| Di | AstraZeneca opens new R&D centre in Cambridge, US | ||
| Mo | Scientists claim Nobel Prize for approach behind light-activated gene therapy | ||
| Mo | FDA approves expanded indication for Lilly's Jaypirca | ||
| Mo | Bayer plans $2.2bn pharmaceutical manufacturing facility in Ohio, US | ||
| 02.10. | AstraZeneca deepens Summit ties on ADC-bispecific cancer combo testing pact | ||
| 01.10. | Varda pockets $251m to back space-based pharma processing mission | ||
| 01.10. | Sanofi and Regeneron expand immunology partnership to the tune of $8bn | ||
| 01.10. | Bristol Myers Squibb secures expanded US approval for Camzyos | ||
| 01.10. | BioMarin and Profluent partner on AI-designed enzyme therapies | ||
| 30.09. | Atossa plans shareholder stake in potential PRV proceeds | ||
| 30.09. | OBIO marks $704m funding milestone for Canadian health tech ventures | ||
| 30.09. | Kyowa Kirin, Knight agree Latin American distribution deal for mogamulizumab |
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.